• 1
    Rawstron AC, Orfao A, Beksac M, Bezdickova L, Brooimans RA, Bumbea H, Dalva K, Fuhler G, Gratama J, Hose D, et al. Report of the European Myeloma Network on multiparametric flow cytometry in multiple myeloma and related disorders. Haematologica 2008; 93: 431438.
  • 2
    Terstappen LWMM, Johnsen S, Segers-Nolten IMJ, Loken MR. Identification and characterization of of plamsa cells in normal human bone marrow by high-resolution flow cytometry. Blood 1990; 76: 17391747.
  • 3
    Wijdenes J, Vooijs WC, Clement C, Post J, Morard E, Vita N, Laurent P, Sun RX, Klein B, Dore JM. A plasmocyte selective monoclonal antibody (B-B4) recognizes syndecan-1. Br J Haematol 1996; 94: 318323.
  • 4
    Bataille R, Jego G, Robillard N, Barille-Nion S, Harousseau JL, Moreau P, Amiot M, Pellat-Deceunynck C. The phenotype of normal, reactive and malignant plasma cells. Identification of “many and multiple myelomas” and new targets for myeloma therapy. Haematologica 2006; 91: 12341240.
  • 5
    Hamilton MS, Ball J, Bromidge E, Franklin IM. Surface antigen expression of human neoplastic plasma cells includes molecules associated with lymphocyte recirculation and adhesion. Br J Haematol 1991; 78: 6065.
  • 6
    Van Camp B, Durie BG, Spier C, De Waele M, Van Riet I, Vela E, Frutiger Y, Richter L, Grogan TM. Plasma cells in multiple myeloma express a natural killer cell-associated antigen: CD56 (NKH-1; Leu-19). Blood 1990; 76: 377382.
  • 7
    Ahsmann EJ, Lokhorst HM, Dekker AW, Bloem AC. Lymphocyte function-associated antigen-1 expression on plasma cells correlates with tumor growth in multiple myeloma. Blood 1992; 79: 20682075.
  • 8
    van Driel M, Günthert U, Stauder R, Joling P, Lokhorst HM, Bloem AC. CD44 isoforms distinguish between bone marrow plasma cells from normal individuals and patients with multiple myeloma at different stages of disease. Leukemia 1998; 12: 18211828.
  • 9
    Guikema JE, Hovenga S, Vellenga E, Conradie JJ, Abdulahad WH, Bekkema R, Smit JW, Zhan F, Shaughnessy J Jr, Bos NA. CD27 is heterogeneously expressed in multiple myeloma: Low CD27 expression in patients with high-risk disease. Br J Haematol 2003; 121: 3643.
  • 10
    Pellat-Deceunynck C, Bataille R, Robillard N, Harousseau JL, Rapp MJ, Juge-Morineau N, Wijdenes J, Amiot M. Expression of CD28 and CD40 in human myeloma cells: A comparative study with normal plasma cells. Blood 1994; 84: 2597603.
  • 11
    Almeida J, Orfao A, Ocqueteau M, Mateo G, Corral M, Caballero MD, Blade J, Moro MJ, Hernandez J, San Miguel JF. High-sensitive immunophenotyping and DNA ploidy studies for the investigation of minimal residual disease in multiple myeloma. Br J Haematol 1999; 107: 121131.
  • 12
    Cannizzo E, Carulli G, Del Vecchio L, Ottaviano V, Bellio E, Zenari E, Azzarà A, Petrini M, Preffer F. The role of CD19 and CD27 in the diagnosis of multiple myeloma by flow cytometry: A new statistical model. Am J Clin Pathol 2012; 137: 377386.
  • 13
    Spears MD, Olteanu H, Kroft SH, Harrington AM. The immunophenotypic stability of plasma cell myeloma by flow cytometry. Int J Lab Hematol 2011; 33: 483491.
  • 14
    Peceliunas V, Janiulioniene A, Matuzeviciene R, Griskevicius L. Six color flow cytometry detects plasma cells expressing aberrant immunophenotype in bone marrow of healthy donors. Cytometry B 2011; 80B: 318323.